Novel compounds in preclinical/early clinical development for the treatment of HIV infections. - Wikidata - wikimedia - TriplyDB

Novel compounds in preclinical/early clinical development for the treatment of HIV infections.

Novel compounds in preclinical/early clinical development for the treatment of HIV infections.

http://www.wikidata.org/entity/Q33966254

about

Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA.Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance Hepatitis B and hepatitis C co-infection in patients with HIV.Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41.Antiviral drugs with extra-cellular sites of action.Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.Topochemical models for prediction of anti-HIV activity of 4-benzyl pyridinone derivatives.New barbiturates and thiobarbiturates as potential enzyme inhibitors.Polyoxometalates as Versatile Enzyme Inhibitors

P2860

Q33853034-B803F17C-8775-4058-8572-13BFDF37DE72 Q34180538-D539CDB8-4F00-483E-A611-E9D6DB36DD0B Q34323219-C439F635-5C1E-4E4D-9385-62A7FA23B39C Q34481618-23FB4455-F922-48CA-9590-AA89364DA6B3 Q35917148-32182AC2-5671-43C1-8956-DFCF6B29C3E4 Q40732790-276A2598-9FA4-466E-9170-678BE17FCE14 Q43759388-5FE459F2-727A-4FD8-B504-6163843E61AC Q44854785-BD578707-4109-43BB-AEEB-6A8662044FDA Q51959150-6E616A65-B0BE-4989-B22A-B20716A6AFC1 Q55057836-EA0C4153-CFA5-4558-AAD4-30D03A9CD5A4 Q57599139-E0146FB2-2E52-442A-B8C8-9B0C1F08AB90

P2860

Novel compounds in preclinical/early clinical development for the treatment of HIV infections.

http://www.wikidata.org/entity/Q33966254

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Novel compounds in preclinical ...... e treatment of HIV infections.

@ast

Novel compounds in preclinical ...... e treatment of HIV infections.

@en

type

label

Novel compounds in preclinical ...... e treatment of HIV infections.

@ast

Novel compounds in preclinical ...... e treatment of HIV infections.

@en

prefLabel

Novel compounds in preclinical ...... e treatment of HIV infections.

@ast

Novel compounds in preclinical ...... e treatment of HIV infections.

@en

P1433

Q33966254-C5E4338E-6E60-4768-9E5B-6F8D4593BBDA

P1476

Q33966254-B9CBC1DD-856B-4A17-B094-B45C1F077A8F

P2093

Q33966254-54B39F52-7BD9-4A3E-9012-3EFECD9BDD0E

P2860

Q33966254-01446D8E-29D7-41CC-B0A0-D1A4DA87A408

Q33966254-0175A66F-48B1-47DE-9FDC-97209C3582C2

Q33966254-02E83EC3-6062-41EC-BC09-4121B0F62AB9

Q33966254-057B0270-8099-4597-B145-2CF63D26D654

Q33966254-07616B9C-6C90-4D68-B380-C753CF24267A

Q33966254-07DF038E-1477-4A2A-B961-10C7D57D6EEB

Q33966254-0910196A-7F44-4318-8949-A6D880BC17BF

Q33966254-10D62E65-CCCA-4C70-A117-E2429B7CD00B

Q33966254-1165ADAB-5FE0-4492-898A-5268ECA63C88

Q33966254-129DBD38-C373-45A0-BC26-96A081B39711

P304

Q33966254-7D5BA8C9-883B-4F3E-88E6-65EBD1628A32

P31

Q33966254-EBA4AF72-B551-40EF-AA74-EEA25E8F3431

P356

Q33966254-7625F103-2349-4C68-8E71-6BCC76BBF86D

P433

Q33966254-23AB205E-416E-4D30-AF8D-913DCAEA31E6

P478

Q33966254-CFB4ED3D-46CD-4319-9663-ADDE6F4E8AB1

P577

Q33966254-A589D501-57CB-409F-A90C-5502F0837549

P698

Q33966254-4AEF189D-9EB9-4CD5-84F0-FD00D538A4DA

P356

08)10:4%3C255::AID-RMV282%3E3.0.CO;2-6

P1433

Reviews in Medical Virology

P1476

Novel compounds in preclinical ...... e treatment of HIV infections.

@en

P2093

De Clercq E

http://www.w3.org/2001/XMLSchema#string

P2860

The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

P304

255-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10891872

http://www.w3.org/2001/XMLSchema#string